Shares in drugmakers AstraZeneca (AZN.L) and Shire (SHP.L) both fell more than 5 percent on Tuesday after the U.S. Treasury took steps to curb "inversion" deals that allow companies to escape high U.S. taxes by reincorporating abroad.
AstraZeneca
Though speculation is rife of a new Pfizer bid, AstraZeneca's chief executive is not holed up with advisers in London or New York. Instead, he has spent the last three days immersed in heart science in Barcelona.
Britain-based AstraZeneca has formed a flagship deal with Medical Research Council or MRC to hopefully help the drugmaker revive research on new drugs, Reuters reported.
AstraZeneca's MedImmune unit has partnered with Immunocore, a private British biotechnology company, to develop a cancer drug that would tap on the body's immune system, Reuters reported.
Shares in Swiss biotech company Actelion rose on Thursday after broker Citi said in a research note British pharma group AstraZeneca might be interested in buying it.
The following bids, mergers, acquisitions and disposals were reported on Friday.
An announcement made last Thursday of a realignment in priority drug research projects prompted Citi analyst to advise shareholders of a possible interest divestment in diabetes drug joint venture between Bristol-Myers Squibb and AstraZeneca.
British drugmaker AstraZeneca announced on Tuesday that it had purchased biotech company Spirogen in a deal worth USD440 million in total.
Merck & Co. decided to cut its annual spending by USD2.5 billion and eliminate more than 10% of its global workers.
AstraZeneca has been looking at another acquisition deal even after spending almost USD1 billion in acquisitions earlier this year.
South Korea-based Celltrion Inc, said in a statement posted on its website, that the stake sale to AstraZeneca by a newspaper was inaccurate, causing the drugmaker's share to slump by 7%.
Pharmaceutical giants Pfizer, AstraZeneca and Novartis are among those to propose bids for Onyx Pharmaceuticals.
AstraZeneca acquired Omthera Pharmaceuticals.
Lowth, current CFO AstraZeneca, will leave this October to become the CFO and Executive Director of BG Group
Vivus investor, First Manhattan Co aimed to replace the drugmaker’s board and management and proposed Anthony Zook to be named company CEO.
Subscribe to VCpost newsletter
Most Popular
- SSI Payment: Double Social Security Benefits in May? Here’s When You Will Receive Yours!
- Joe Biden Administration Sanctions Hundreds of Companies to Choke Russia's Supplies of Military Technology
- IRS Scrambles to Address Huge Gap in Audit Rates Between Black, Other Taxpayers
- US Accuses Russia of Quietly Shipping Refined Petroleum to North Korea at Levels Violating UN Cap
- Affordable Connectivity Program: Congress Fights to Refuel Low-Cost Broadband Program Amid Looming Expiration
- Former Seafood Giant Red Lobster Nears Bankruptcy Due To Declining Sales and Mismanagement
- MeTV Unveils Toons Network Dedicated to Showcasing Warner Bros. Classics; List of Cartoons Revealed
- Former Trump Aide Hope Hicks to Marry Goldman Sachs Exec Jim Donovan